PCVX

Vaxcyte, Inc.

A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.

Recent Activity

Show $

2026Q2

2 buys2 sells

ArrowMark PartnersEXIT

-40.0K shares

ArrowMark PartnersEXIT

-40.0K shares

Baupost Group LLCEXIT

-800.0K shares

Baupost Group LLCEXIT

-800.0K shares

Bridgewater Associates LPADD

+37.3K shares(+289.2%)

Bridgewater Associates LPADD

+37.3K shares(+289.2%)

Maverick CapitalADD

+235.5K shares(+17.1%)

Maverick CapitalADD

+235.5K shares(+17.1%)

2026Q1

3 buys

Baupost Group LLCNEW

+800.0K shares

Baupost Group LLCNEW

+800.0K shares

Bridgewater Associates LPNEW

+12.9K shares

Bridgewater Associates LPNEW

+12.9K shares

Maverick CapitalADD

+23.5K shares(+1.7%)

Maverick CapitalADD

+23.5K shares(+1.7%)

Loading more activity...